72 results
8-K
EX-99.1
ME
23andMe Holding Co - Ordinary Shares
31 Jan 24
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
7:50am
enhanced, which provides an additional mechanism for NK cells to induce cell death of ULBP6-expressing cancer cells.
'1473 also has the potential
8-K
EX-99.2
ME
23andMe Holding Co - Ordinary Shares
8 Jan 24
Regulation FD Disclosure
7:45am
to isotype control. * p-value<=0.05 compared to control PBMC, peripheral blood mononuclear cell; PD-1, programmed death–1; SEB, staphylococcal
8-K
EX-99.1
ME
23andMe Holding Co - Ordinary Shares
8 Jan 24
Regulation FD Disclosure
7:45am
improve and expand product offerings. Product prices as of 12/31/23.
10Copyright © 2024 23andMe, Inc. U.S. Leading Causes of Death Genetics plays a role … in 9 of the 10 leading causes of death in the US1 = Addressed by 23andMe genetic report Heart disease Cancer COVID-19 Accidents (unintentional
S-8
EX-99.1
od2atar
15 Sep 23
Registration of securities for employees
4:06pm
DEFR14A
yhjeb1mqz3hkf37
4 Aug 23
Revised proxy
4:05pm
DEFR14A
cfceacnuwe4z
26 Jul 23
Revised proxy
9:14pm
8-K
EX-99.1
udqrhrhb
17 Apr 23
Regulation FD Disclosure
4:10pm
8-K
EX-3.1
082bp0359t0jm
9 Dec 22
Departure of Directors or Certain Officers
8:05am
8-K
EX-99.1
4j0yop1jz
9 Nov 22
Investor Presentation November 2022
7:30am
8-K
EX-99.1
z2v8f3rg3l2
7 Nov 22
23andMe Reports FY2023 Second Quarter Financial Results
4:06pm
POS AM
l9m1kv32x0ji9j vfzai
3 Nov 22
Prospectus update (post-effective amendment)
4:14pm